Myasthenia gravis
Adjust the patient characteristics. Results update as you go. Full criteria table
Draft. Coverage criteria for myasthenia gravis therapies in Alberta. The special authorization criteria for efgartigimod, ravulizumab, rozanolixizumab and zilucoplan are verified verbatim against Alberta Drug Benefit List Section 3 effective April 1, 2026. Entries for conventional therapies and for private and federal payers remain draft.